Clinical Benefits of Concurrent Capecitabine and Cisplatin versus Concurrent Cisplatin and 5-Flurouracil in Locally Advanced Squamous Cell Head and Neck Cancer

drug discoveries & therapeutics

Volumn 7, Issue 1, 2013, Pages 36-42

  Gupta, Seema ^a   Khan, Huma ^a   Barik, Sandip ^a   Negi, M P S ^b  

^a KING GEORGE'S MEDICAL UNIVERSITY   (India)

^b Institute for Data Computing and Training   (India)

Author keywords

capecitabine; chemoradiation; Head and neck cancer

Indexed keywords

EID: 85008750022     PISSN: 18817831     EISSN: 1881784x     Source Type: Journal    
DOI: 10.5582/ddt.2013.v7.1.36     Document Type: Article

References (24)

1. Al-Sarraf M. Treatment of locally advanced head and neck cancer: Historical and critical review. Cancer Control. 2002; 9:387-399.
2. Calais G, Alfonsi M, Bardet E, Sire C, Germain T, Bergerot P, Rhein B, Tortochaux J, Oudinot P, Bertrand P. Randomized trial of radiation therapy versus concomitant chemotherapy and radiation therapy for advanced-stage oropharynx carcinoma. J Natl Cancer Inst. 1999; 91:2081-2086.
3. Pignon JP, Bourhis J, Domenge C, Designé L. Chemotherapy added to locoregional treatment for head and neck squamous-cell carcinoma: Three meta-analyses of updated individual data. MACH-NC Collaborative Group. Meta-Analysis of Chemotherapy on Head and Neck Cancer. Lancet. 2000; 355:949-955.
4. Wendt TG, Grabenbauer GG, Rödel CM, Thiel HJ, Aydin H, Rohloff R, Wustrow TP, Iro H, Popella C, Schalhorn A. Simultaneous radiochemotherapy versus radiotherapy alone in advanced head and neck cancer: A randomized multicenter study. J Clin Oncol. 1998; 16:1318-1324.
5. Kohno N, Kitahara S, Tamura E, Tanabe T. Concurrent chemoradiotherapy with low-dose cisplatin plus 5-fluorouracil for the treatment of patients with unresectable head and neck cancer. Oncology. 2002; 63:226-231.
6. Forastiere AA, Goepfert H, Maor M, Pajak TF, Weber R, Morrison W, Glisson B, Trotti A, Ridge JA, Chao C, Peters G, Lee DJ, Leaf A, Ensley J, Cooper J. Concurrent chemotherapy and radiotherapy for organ preservation in advanced laryngeal cancer. N Engl J Med. 2003; 349:2091-2098.
7. Lin JC, Jan JS, Hsu CY, Liang WM, Jiang RS, Wang WY. Phase III study of concurrent chemoradiotherapy versus radiotherapy alone for advanced nasopharyngeal carcinoma: Positive effect on overall and progression-free survival. J Clin Oncol. 2003; 21:631-637.
8. Schuller J, Cassidy J, Dumont E, Roos B, Durston S, Banken L, Utoh M, Mori K, Weidekamn E, Reigner B. Preferential activation of patients. Cancer Chemother Pharmacol. 2000; 34:293-296.
9. Sawada N, Ishikawa T, Sekiguchi F, Tanaka Y, Ishitsuka H. X-ray irradiation induces thymidine phosphorylase and enhances the efficacy of capecitabine (Xeloda) in human cancer xenografts. Clin Cancer Res. 1999; 5:2948-2953.
10. Pivot X, Chamorey E, Guardiola E, Magné N, Thyss A, Otto J, Giroux B, Mouri Z, Schneider M, Milano G. Phase I and pharmacokinetic study of the association of capecitabine-cisplatin in head and neck cancer patients. Ann Oncol. 2003; 14:1578-1586.
11. Kim JG, Sohn SK, Kim DH, Baek JH, Jeon SB, Chae YS, Lee KB, Park JS, Sohn JH, Kim JC, Park IK. Phase II study of concurrent chemoradiotherapy with capecitabine and cisplatin in patients with locally advanced squamous cell carcinoma of the head and neck. Br J Cancer. 2005; 93:1117-1121.
12. Kim JC, Kim TW, Kim JH, Yu CS, Kim HC, Chang HM, Ryu MH, Park JH, Ahn SD, Lee SW, Shin SS, Kim JS, Choi EK. Preoperative concurrent radiotherapy with capecitabine before total mesorectal excision in locally advanced rectal cancer. Int J Radiat Oncol Biol Phys. 2005; 63:346-353.
13. Yu CS, Kim TW, Kim JH, Choi WS, Kim HC, Chang HM, Ryu MH, Jang SJ, Ahn SD, Lee SW, Shin SS, Choi EK, Kim JC. Optimal time interval between capecitabine intake and radiotherapy in preoperative chemoradiation for locally advanced rectal cancer. Int J Radiat Oncol Biol Phys. 2007; 67:1020-1026.
14. Tunio MA, Hashmi AH. Capecitabine initially concomitant to radiotherapy then perioperatively administered in locally advanced rectal cancer. In regard to MG Zampino et al. (Int J Radiat Oncol Biol Phys 2009; 75:421-427). Int J Radiat Oncol Biol Phys. 2010; 76:1275.
15. Kim TW, Chang HM, Kang HJ, Lee JR, Ryu MH, Ahn JH, Kim JH, Lee JS, Kang YK. Phase II study of capecitabine plus cisplatin as first-line chemotherapy in advanced biliary cancer. Ann Oncol. 2003; 14:1115-1120.
16. Kim TW, Kang YK, Ahn JH, Chang HM, Yook JH, Oh ST, Kim BS, Lee JS. Phase II study of capecitabine plus cisplatin as first-line chemotherapy in advanced gastric cancer. Ann Oncol. 2002; 13:1893-1898.
17. Park JH, Kim JH, Ahn SD, Lee SW, Shin SS, Kim JC, Yu CS, Kim HC, Kang YK, Kim TW, Chang HM, Ryu MH, Choi EK. Prospective phase II study of preoperative chemoradiation with capecitabine in locally advanced rectal cancer. Cancer Res Treat. 2004; 36:354-359.
18. Van Cutsem E, Twelves C, Cassidy J, et al. Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer: Results of a large phase III study. J Clin Oncol. 2001; 19:4097-4106.
19. Blum JL, Jones SE, Buzdar AU, LoRusso PM, Kuter I, Vogel C, Osterwalder B, Burger HU, Brown CS, Griffin T. Multicenter phase II study of capecitabine in paclitaxel-refractory metastatic breast cancer. J Clin Oncol. 1999; 17:485-493.
20. Chargari C, Kirova YM, Diéras V, Castro Pena P, Campana F, Cottu PH, Pierga J, Fourquet A. Concurrent capecitabine and whole-brain radiotherapy for treatment of brain metastases in breast cancer patients. J Neurooncol. 2009; 93:379-384.
21. Bensadoun RJ, Magné N, Marcy PY, Demard F. Chemotherapy-and radiotherapy-induced mucositis in head and neck cancer patients: New trends in pathophysiology, prevention and treatment. Eur Arch Otorhinolaryngol. 2001; 258:481-487.
22. Trotti A. Toxicity in head and neck cancer: A review of trends and issues. Int J Radiat Oncol Biol Phys. 2000; 47:1-12.
23. Adelstein DJ, Li Y, Adams GL, Wagner H Jr., Kish JA, Ensley JF, Schuller DE, Forastiere AA. An intergroup phase III comparison of standard radiation therapy and two schedules of concurrent chemoradiotherapy in patients with unresectable squamous cell head and neck cancer. J Clin Oncol. 2003; 21:92-98.
24. Yang GY, Thomas CR. Can the sequencing of concurrent capecitabine and radiation therapy improve the therapeutic ratio in rectal cancer? Gastrointest Cancer Res. 2007; 1:64-65.